Axillary recurrence was rare among patients who skipped standard axillary lymph node dissection after being downstaged to node-negative disease, a recent analysis found.
Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, and these rates did not differ significantly between patients who underwent sentinel lymph node biopsy or targeted axillary dissection, new research suggests.
To investigate, researchers looked back at 1144 patients with stages II-III biopsy-proven node-positive breast cancer treated with neoadjuvant chemotherapy across 25 centers in 11 countries; 93% of patients had N1 disease, 54% had ERBB2 –positive illness, and 66% had a breast pathologic complete response.
The primary endpoints were 3- and 5-year rates of any axillary recurrence. Secondary endpoints included locoregional recurrence, any invasive recurrence, and number of lymph nodes removed.Patients who underwent targeted axillary dissection were more likely to receive nodal radiation therapy . The clipped node was successfully retrieved in 97% of targeted axillary dissection cases and 86% of sentinel lymph node biopsy cases .
Malignant Breast Neoplasm Breast Carcinoma Sentinel Lymph Node Biopsy Sentinel Node Procedure Lymph Node Dissection Sentinel Lymph Node Lymph Nodes Biopsy Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Breast Mammary Gland Chemotherapy Neoadjuvant
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Omitting axillary lymph node dissection does not increase the risk for recurrence or compromise 5-year overall survival outcomes in patients with early-stage, node-negative breast cancerA trial with a large cohort of patients with early-stage, node-negative breast cancer showed that skipping axillary lymph node dissection does not affect recurrence risk or 5-year overall survival outcomes. The study aimed to fill the gaps in the literature and provide more evidence on the topic.
Read more »
Is Axillary Surgery in Early Breast Cancer on Its Way Out?Omitting axillary surgery in patients with early breast cancer who had sentinel-node metastases and underwent surgery and radiotherapy did not compromise survival outcomes, new data show.
Read more »
CARV Announces up-to-100% Node Buyback Program to Chaperone its Node Launch and Hyperscale its Data LayerCARV Announces up-to-100% Node Buyback Program to Chaperone its Node Launch and Hyperscale its Data Layer
Read more »
Sophon ZKSync hyperchain raises $60 million in node saleSophon, an entertainment-focused zkSync Hyperchain, raises $60 million in wETH through a node sale to launch an AI and gaming ecosystem leveraging Zero Knowledge (ZK) technology.
Read more »
zkSync 'hyperchain' Sophon raises $60 million via node saleSophon, a zkSync 'hyperchain' or a Layer 2 network being built using Matter Labs' ZK Stack, has raised around $60 million via a node sale.
Read more »
The Protocol: From 'Node Sales' to 'Address Poisoning,' the Money's in CryptoBradley Keoun is the managing editor of CoinDesk's Tech & Protocols team. He owns less than $1,000 each of several cryptocurrencies.
Read more »